Resumo

CLIMENT BALLESTER, S  e  POLACHE VENGUD, J. Management of HCV infection in coinfected patient after vagal syncope secondary to sofosvubir/ledipasvir. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.2, pp.152-154.  Epub 15-Mar-2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000200018.

Infection with the hepatitis C virus (HCV) is a public health problem1. In 2015, new direct-acting antiviral drugs (ADA) were commercialized in Spain, capable of eliminating the sustained viral replication in more than 90% of infected patients2. AAD drugs have an excellent safety profile and the duration of treatment is limited to 8, 12 or 24 weeks depending on a series of parameters3,4. Health professionals have to work as a team to select the most appropriate treatment for each patient taking into account their clinical situation, comorbidities and concomitant treatments. In 2015, the existence of patients with HIV infection coinfected with HCV was approximately 20%5, making it essential to choose the therapeutic plan with the best interaction profile. We describe the case of a patient coinfected with HIV and HCV that presents an adverse reaction (RA), a vagal syncope, to the first administration of sofosbuvir/ledipasvir and that is repeated to the second administration, ruling out this treatment definitively.

Palavras-chave : Hepatitis C; direct acting antivirals; sofosbuvir; ledipasvir; grazoprevir; elbasvir; adverse events; vasovagal syncope.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )